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Abstract
Background: The "integrated safety report" of the drug registration files submitted to health
authorities usually summarizes the rates of adverse events observed for a new drug, placebo or
active control drugs by pooling the safety data across the trials. Pooling consists of adding the
numbers of events observed in a given treatment group across the trials and dividing the results by
the total number of patients included in this group. Because it considers treatment groups rather
than studies, pooling ignores validity of the comparisons and is subject to a particular kind of bias,
termed "Simpson's paradox." In contrast, meta-analysis and other stratified analyses are less
susceptible to bias.
Methods: We use a hypothetical, but not atypical, application to demonstrate that the results of
a meta-analysis can differ greatly from those obtained by pooling the same data. In our hypothetical
model, a new drug is compared to 1) a placebo in 4 relatively small trials in patients at high risk for
a certain adverse event and 2) an active reference drug in 2 larger trials of patients at low risk for
this event.
Results: Using meta-analysis, the relative risk of experiencing the adverse event with the new drug
was 1.78 (95% confidence interval [1.02; 3.12]) compared to placebo and 2.20 [0.76; 6.32]
compared to active control. By pooling the data, the results were, respectively, 1.00 [0.59; 1.70]
and 5.20 [2.07; 13.08].
Conclusions: Because these findings could mislead health authorities and doctors, regulatory
agencies should require meta-analyses or stratified analyses of safety data in drug registration files.
Introduction
The drug registration files submitted to European and US
health authorities present overall safety data in an "inte-
grated safety report," which takes into account all the clin-
ical trials that were performed during the development of
the new product. In the standard integrated safety report,
rates of adverse events observed with the new drug, place-
bo or active control drugs are calculated by pooling data
across the trials. Pooling, the simplest and most naively
intuitive way of summarizing the information from sever-
al clinical trials, consists of adding the number of events
observed in a given group, and dividing the results by the
total number of patients included in this group. For exam-
ple, the number of headaches in the new drug group is ob-
tained by adding the numbers of headaches reported in all
groups that received the new drug in clinical trials, regard-
less of control group. To obtain the pooled rate of head-
ache, this number is divided by the total number of
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patients who received the new drug. Similar pooling is
done in the placebo and, if applicable, active control
groups. The proportion of events is thus obtained for each
treatment group, and the relative risk of developing the
event is the ratio of the rate in the active group to the rate
in the control group. Because pooling focuses on treat-
ment groups rather than on studies, this approach does
not consider the validity of the comparisons and, there-
fore, is subject to a bias termed "Simpson's paradox in
probability" (also known in epidemiology as "confusion
bias" [1,2]. A more satisfactory technique involves com-
bining the results of each trial, expressed for example as
relative risks. This latter technique is used in stratified
analyses, and, particularly, in meta-analyses.
The results of a stratified analysis or a meta-analysis can
differ greatly from those obtained by pooling the same da-
ta, as shown by the following example. This phenomenon
may hamper the accurate evaluation of safety by regulato-
ry agencies during the drug registration process. We pro-
pose that safety be assessed using meta-analytic
techniques.
Methods
Ideally, we would use an example from original material
submitted by pharmaceutical firms to regulatory agencies.
Such material, however, is confidential and cannot be
found in publications. Instead, we provide numbers from
a hypothetical, but not atypical, application (part IV of in-
ternational drug registration dossiers), where a new drug
is compared to 1) a placebo in 4 relatively small trials of
patients at high risk for a certain adverse event (referred to
as the "event"), and 2) an active reference drug in 2 larger
trials of patients at low risk for this event. All trials were of
the same duration, and the risk of developing the event is
higher in the treated group. Sample sizes and number of
events are presented in Table 1.
The results of the trials can be pooled as described above,
and can also be analyzed by meta-analytic techniques. In
this example, the meta-analysis was performed using the
logarithmic mean of the relative risk weighted by the in-
verse of its variance [3]. The calculations were performed
using EasyMA software [4].
Results
Pooling the data yields the following proportions (no.
events/no. participants): new drug group (studies 1–6):
45/3,460 = 1.30%; placebo group (studies 1–4): 19/1,460
= 1.30%; active control group (studies 5–6): 5/2,000 =
0.25%.
Table 2 presents the relative risk for developing the event
for the new drug compared with placebo or active control
(and the respective 95% confidence intervals). P-values
were calculated by Fisher's exact test for pooled relative
risks. The results of the meta-analysis are presented with
the usual association and heterogeneity p-values.
The two methods give very different results. The pooled
analysis shows the same risk for the event with the new
drug and placebo, although the risk was, in fact, greater in
the new drug than in the placebo group in studies 2, 3 and
4 and the same in study 1 (Table 1). The pooled risk of
event in the new drug group was more than five times that
in the active control group, although the difference was
much less pronounced in studies 5 and 6. Conversely, the
meta-analysis showed that the rate of developing the
event was significantly increased in the new drug group
compared with the placebo group, and the event rate was
increased only 2.2 times in the new drug compared with
the active control group, a non-significant increase. The
results of the meta-analysis agree with the results of the in-
dividual trials. The non-significant p-values testing for
heterogeneity imply that the data show no evidence of in-
consistency across the different studies.
Table 1: Results of four hypothetical placebo-controlled (1–4) and two active treatment-controlled (5 and 6) studies: number of events/
number of patients in each group.
Study New drug Placebo-controls Active-treatment 
controls
Relative Risk
1 2/60 2/60 – 1.0
2 9/400 5/400 – 1.8
3 10/500 5/500 – 2.0
4 13/500 7/500 1.6
5 5/1000 – 2/1000 2.5
6 6/1000 – 3/1000 2.0Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/6
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Discussion
Practical consequences
Simpson's paradox arises when validity of the compari-
sons is ignored, and when there is a large imbalance of a
factor at the different levels of the variable of interest [1,2].
In the above example, Simpson's paradox arose in the
pooling process and caused a discrepancy between the
pooling and the meta-analysis results. This discrepancy
occurred because the risks of the populations included in
the placebo- and active drug-controlled studies differed
greatly, and the comparison considered treatment groups
rather than studies. A similar imbalance may arise if dis-
eases or disease stages are different, or if patients are re-
cruited from different settings (e.g., in hospital for
placebo-controlled trials and from the community for ac-
tive drug-controlled trials). It can also be the case when
variable follow-up duration is not taken into account.
These data are hypothetical, yet they reflect a number of
actual small or medium-sized placebo-controlled efficacy
studies, as well as larger studies comparing new drugs to
already existing competitors. These hypothetical data are
not unusual; similar data arise commonly in practice.
Although for some time, pooling has been considered in-
adequate for the assessment of efficacy [5], it still repre-
sents the usual approach for presenting safety data in the
integrated safety report of application files submitted by
the pharmaceutical industry to regulatory agencies. Cases
similar to our example may, therefore, be encountered
and may mislead the experts who evaluate these applica-
tions. This is particularly true for relatively frequent events
for which the usual pharmacovigilance approach–based
on imputation of individual cases of rare events–is unable
to detect an increased risk. In the above scenario, although
the absolute risk was not negligible, the numbers of events
were small in each trial and the increase in risk would
have probably been overlooked at the trial level.
Drug agency experts may perform meta-analyses or strati-
fied analyses on safety data; however, this is not common
practice, perhaps because of force of habit and/or the en-
suing workload, given the very strict time frame in which
application files must be submitted.
Recommendation: the integrated safety report should 
change
The usual way of summarizing safety data in drug applica-
tion files submitted by the pharmaceutical industry to reg-
ulatory agencies is potentially misleading. Pooled safety
information about new drugs may underestimate the risk
of some adverse events and overestimate others. In some
instances, it may lead to approval of a drug with an unac-
ceptable safety profile. Such oversights harm both physi-
cians and patients, since safety data (in contrast to efficacy
data) are seldom available in published clinical trial re-
ports.
The end-users of drugs cannot verify the appropriateness
of the safety information given by the Summary of Prod-
uct Characteristics. They must rely on the assessment of
the regulatory agencies. Meta-analysis, or equivalently,
stratifying by study, is the only approach that can reliably
summarize safety data from several clinical trials because
it focuses on studies rather than treatment groups, and
maintains the validity of the comparisons. A limitation to
meta-analysis is found when data are very sparse, for ex-
ample, when a high proportion of zero events exist in tri-
als. In this situation, meta-analysis is biased, although it
remains the best method to summarize the data. None-
theless, statistical power would be so low that results
could not be interpreted and the pharmacovigilance ap-
proach would, instead, be appropriate. Another potential
pitfall would be to include in the same meta-analysis all
trials that have assessed the new drug, regardless of the
control group. Such a meta-analysis would be invalid,
since it may combine trials that are not comparable and
relative risks that cannot be interpreted in the same way.
Regulatory agencies should require meta-analyses or strat-
ified analyses of safety data for adverse events that are
common enough to be reported in nearly all the clinical
trials in an application.
Table 2: Relative risks of events and 95% confidence intervals obtained by pooling data or performing a meta-analysis.
Relative risk (pooling) Relative risk (meta-analysis)
New drug versus placebo 1.00 [0.59; 1.704], p= 1.00 1.78 [1.02; 3.12]
association p = 0.04
heterogeneity p = 0.94
New drug versus active control 5.20 [2.07; 13.08], p = 0.00004 2.20 [0.76; 6.32]
association p = 0.14
heterogeneity p = 0.84Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/6
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